Pharsight

Drugs that contain Tecovirimat

1. Tpoxx patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8124643 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

US9339466 SIGA TECHNOLOGIES Polymorphic forms of ST-246 and methods of preparation
Mar, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802714 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

US8530509 SIGA TECHNOLOGIES Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jun, 2024

(2 months from now)

US8039504 SIGA TECHNOLOGIES Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Jul, 2027

(3 years from now)

US9907859 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(7 years from now)

US9233097 SIGA TECHNOLOGIES ST-246 liquid formulations
Aug, 2031

(7 years from now)

US10576165 SIGA TECHNOLOGIES ST-246 liquid formulations and methods
Aug, 2031

(7 years from now)

US7737168 SIGA TECHNOLOGIES Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Sep, 2031

(7 years from now)

US11890270 SIGA TECHNOLOGIES Polymorphic forms of ST-246 and methods of preparation
Aug, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 13, 2023

NCE-1 date: 2022-07-13

Market Authorisation Date: 18 May, 2022

Treatment: Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg; Tpoxx is indicated for the treatment of human smallpox disease in adults and pedia...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

TPOXX family patents

Family Patents